EXHIBIT 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

ConfidentialPage # 1

AMENDMENT #3

TO EXCLUSIVE LICENSE AGREEMENT # 2

WHEREAS Reva Medical Inc. (“REVA”) and Rutgers, The State University of New Jersey (“Rutgers”), referred to collectively herein as “the Parties”, entered into an EXCLUSIVE LICENSE AGREEMENT NUMBER 2 (“License #2) effective July 1, 2010; and,

WHEREAS Section 6.3 (i)(b) of License #2, as amended by the signed Request for Extension letter dated July 1, 2014, requires REVA to file an application with the USFDA or a comparable agency in another Major Market Country no later than the end of 2015; and

WHEREAS Section 6.3 (ii) (b), as amended by Amendment #2, requires REVA to Pay Rutgers an annual amount of $[***] in order to extend REVA’s rights in the field of Non-Stent Products for as long as the necessary regulatory filing for Non-Stent Product has not been effected;

THEREFORE, the Parties hereby mutually agree to amend License #2 as of August 31, 2016 as follows:

“Licensee or its Sublicensees will submit a complete application to either an appropriate regulatory body in the European Community or to the USFDA for a CE Marking or a Pre-Market Approval for at least one Coronary Stent Product, not later than by September 1, 2016.”

_________________

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

ConfidentialPage # 2

“Starting on June 30, 2016, for each annual filing extension desired by Licensee, Licensee will pay Rutgers an amount of $[***] on July 1 of the year for which the extension is granted, and an additional amount of $[***] immediately upon the earliest to occur of the following events:

IN WITNESS HEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

_________________

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.